Cardiff Oncology, Inc. (CRDF) Dividend History

Company News

• Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

  The global cancer market is projected to surpass $900 billion by 2034, driven by advancements in cancer treatments from biotech companies like Oncolytics Biotech, Exelixis, Cardiff Oncology, ALX Oncology, and Verastem.

  Benzinga

  Featured Companies: ALXO EXEL ONCY VSTM
• Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

  Cardiff Oncology, a clinical-stage biotechnology company, announced the pricing of a $40 million underwritten offering of its common stock. The company plans to use the proceeds to fund clinical trials for its lead asset, onvansertib, in metastatic colorectal cancer and pancreatic cancer.

  Benzinga
• Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

  Cardiff Oncology announced positive initial data from a randomized Phase 2 trial evaluating onvansertib in combination with standard-of-care in patients with first-line RAS-mutated metastatic colorectal cancer. The 30mg dose of onvansertib demonstrated a 64% objective response rate, significantly higher than the 33% rate in the control arm.

  GlobeNewswire Inc.
• Cardiff Oncology to Present at the Jefferies Healthcare Conference

  SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 5-6, 2024.

  GlobeNewswire Inc.
• Cardiff Oncology to Present at Upcoming Investor Conferences in May

  SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024.

  GlobeNewswire Inc.